Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.
Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group. Powis J, et al. Among authors: yoshida em. J Viral Hepat. 2008 Jan;15(1):52-7. doi: 10.1111/j.1365-2893.2007.00889.x. J Viral Hepat. 2008. PMID: 18088245 Free PMC article. Clinical Trial.
Late acute rejection after liver transplantation: the Western Canada experience.
Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, Steinbrecher UP, Gutfreund KS, Erb SR, Partovi N, Chung SW, Shapiro J, Wong WW. Ramji A, et al. Among authors: yoshida em. Liver Transpl. 2002 Oct;8(10):945-51. doi: 10.1053/jlts.2002.34969. Liver Transpl. 2002. PMID: 12360439 Free article.
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Rasenack J, et al. Among authors: yoshida em. Pharmacoeconomics. 2003;21(5):341-9. doi: 10.2165/00019053-200321050-00005. Pharmacoeconomics. 2003. PMID: 12627987 Clinical Trial.
Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K. Greig P, et al. Liver Transpl. 2003 Jun;9(6):587-95. doi: 10.1053/jlts.2003.50102. Liver Transpl. 2003. PMID: 12783400 Free article. Clinical Trial.
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM. Chatur N, et al. Among authors: yoshida em. Liver Int. 2005 Aug;25(4):723-7. doi: 10.1111/j.1478-3231.2005.01107.x. Liver Int. 2005. PMID: 15998421 Clinical Trial.
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Yoshida EM, et al. Liver Transpl. 2005 Sep;11(9):1064-72. doi: 10.1002/lt.20490. Liver Transpl. 2005. PMID: 16123958 Free article. Clinical Trial.
448 results